Koshinski Asset Management, Inc. Annovis Bio, Inc. Transaction History

Koshinski Asset Management, Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2023 Apr 12, 2023	BUY	$12.33 - $22.1 $61,650 - $110,500	5,000 Added 50.0%	15,000 $231,000
Q2 2022 Jul 12, 2022	BUY	$8.61 - $13.87 $86,100 - $138,700	10,000 New	10,000 $113,000

1.2M

779K

1.77M

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $45.4M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Koshinski Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Koshinski Asset Management, Inc. with notifications on news.